Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis.
A total of forty patients participated in an open, randomized study to compare the efficacy and toleration of a single dose of topical tioconazole 6% vaginal ointment with 5 days treatment of systemic ketoconazole (400 mg/day) in patients with symptomatic vaginal candidal infection. Disease in patients of both treatment groups was effectively eradicated after 5 weeks of therapy. Symptoms of patients receiving topical therapy responded more quickly than those of patients receiving oral therapy. Side-effects were more prevalent with ketoconazole systemic therapy. Overall, topical therapy with tioconazole was preferred over systemic ketoconazole therapy for these women with symptomatic vulvovaginitis due to Candida albicans.
D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D007654:Ketoconazole / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011897:Random Allocation; D013997:Time Factors
D000935:Antifungal Agents; D007093:Imidazoles; D007654:Ketoconazole; C020527:tioconazole